About Us
Our eyes are a tool for much more than vision. We use them to connect and communicate with the people and the world around us. Cloudbreak Pharma is on a mission to ensure no one is held back by poor eye health. We aim to help people prosper by treating a variety of eye conditions that compromise vision and quality of life.
We are a clinical-stage global biotechnology company developing ophthalmic drugs for chronic eye diseases which are often with few treatment options. Our broad pipeline was developed by in-house scientists with the experience and expertise to identify new targeted mechanisms of action and craft formulations that are amenable to topical ocular delivery. Our deep understanding of ophthalmic disease pathogenesis and extensive scientific know-how led us to our lead pipeline candidate, CBT-001 – an investigational eye drop treatment with the potential to slow or stop progression of pterygium, a highly underdiagnosed and undertreated disease with no approved drug therapy.
Management
Jinsong Ni, Ph.D
Founder, Chief Executive Officer
Rebecca Chan, CPA, MBA, LLB
Director, Chief Financial Officer
Abu Abraham, MD
Chief Medical Officer
Van Dinh, MBA
Chief Operating Officer
Rong Yang, Ph.D
Chief Scientific Officer
Greg Brooks, B.Sc
Chief Commercial Officer
Scientific Advisory Board
Our Partners
Santen Pharmaceutical Co., Ltd.
(TYO:4536)
In August 2024, Cloudbreak and Santen entered into a licensing agreement for CBT-001, Cloudbreak’s investigational proprietary multi-kinase inhibitor for the treatment of pterygium in, to develop, manufacture and commercialize the drug products in Japan, South Korea, Vietnam, Thailand, Malaysia, Philippines, Singapore, and Indonesia.
Grand Pharma
(00512.HK)
In April 2020, Cloudbreak and Grand Pharma entered into a commercialisation licensing arrangement which Grand Pharma is granted with an exclusive, sublicensable, royalty-bearing license to manufacture and commercialise CBT-001 in mainland China, Hong Kong, Macau and Taiwan region.